NEW YORK (GenomeWeb News) – Horizon Discovery today said that it has signed a supply and distribution agreement enabling it to offer its customers access to Sirion Biotech's RNAiONE custom short hairpin RNA development services.
In addition, Cambridge, UK-based Horizon said that it also would offer Sirion's off-the-shelf shRNA and cDNA over-expression reagents. It said the reagents would be available as transduction-ready lentivirus particles or as plasmids.
Horizon also said that Sirion's RNAiONE platform produces shRNAs "with a gene silencing efficiency often greater than 90 percent."
"Issues surrounding knockdown efficiency and the associated phenotypic variation have led to inconsistent results," Jon Moore, VP of oncology for Horizon, said in a statement. "The high silencing efficiency ensured by RNAiONE gives researchers confidence in their functional genomics investigations."
Financial and other terms of the alliance were not disclosed.